Press coverage about Teligent (NASDAQ:TLGT) has been trending somewhat positive on Friday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Teligent earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.9278869990966 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of equities research analysts have weighed in on TLGT shares. Canaccord Genuity reduced their price objective on Teligent from $4.00 to $3.50 and set a “hold” rating for the company in a research note on Friday, March 2nd. Zacks Investment Research upgraded Teligent from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Teligent presently has an average rating of “Hold” and an average price target of $7.00.
Teligent stock opened at $3.17 on Friday. Teligent has a 12 month low of $2.43 and a 12 month high of $9.54. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.68 and a quick ratio of 2.01. The company has a market cap of $174.40, a PE ratio of -16.68 and a beta of 0.72.
TRADEMARK VIOLATION NOTICE: This article was originally published by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-teligent-tlgt-share-price/2030114.html.
Teligent Company Profile
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.